BIOCRYST PHARMACEUTICALS (BCRX) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
BIOCRYST PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 4 sold $4.1M of BCRX stock on the open market.
Get emailed when insiders cluster-buy stocks like BCRX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
BCRX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | $697K | 2 |
| Q1 2026 | — | 0 | $1.9M | 2 |
| Q4 2025 | — | 0 | $1.6M | 6 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 BIOCRYST PHARMACEUTICALS INC insiders reported open-market purchases totaling $0, while 4 insiders reported sales totaling $4.1M. 8 of 10 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| May 19SEC | Amy E MckeeDirector | Sell | 11,18031,252 held (−26%) | $8.97 | $100K | -4.7% | — |
| May 15SEC | Alane P BarnesGeneral Counsel | Sell Plan | 62,500400,703 held (−13%) | $9.54 | $596K | -10.4% | — |
| Mar 24SEC | Theresa HeggieDirector | Sell | 49,93365,352 held (−43%) | $10.11 | $505K | -15.4% | — |
| Mar 18SEC | Alane P BarnesGeneral Counsel | Sell Plan | 150,000400,703 held (−27%) | $9.15 | $1.4M | -6.6% | — |
| Dec 23SEC | Alane P BarnesGeneral Counsel | Sell Plan | 21,773398,751 held (−5%) | $7.65 | $167K | +11.8% | — |
| Dec 16SEC | Alane P BarnesGeneral Counsel | Sell Plan | 21,210315,726 held (−6%) | $7.65 | $162K | +11.8% | — |
| Dec 3SEC | Alane P BarnesGeneral Counsel | Sell Plan | 91,004416,152 held (−18%) | $7.10 | $646K | +20.4% | — |
| Dec 3SEC | Alane P BarnesGeneral Counsel | Sell Plan | 50,906365,246 held (−12%) | $7.21 | $367K | +18.6% | — |
| Dec 3SEC | Alane P BarnesGeneral Counsel | Sell Plan | 19,770345,476 held (−5%) | $7.65 | $151K | +11.8% | — |
| Nov 17SEC | Machelle SandersDirector | Sell Plan | 9,60030,642 held (−24%) | $7.14 | $69K | +19.7% | — |
Insiders at BIOCRYST PHARMACEUTICALS INC
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Alane P BarnesGeneral Counsel | — | $3.5M | May 15, 2026 | — |
| Theresa HeggieDirector | — | $505K | Mar 24, 2026 | — |
| Amy E MckeeDirector | — | $100K | May 19, 2026 | — |
| Machelle SandersDirector | — | $69K | Nov 17, 2025 | — |
BCRX stock: common questions
Are BIOCRYST PHARMACEUTICALS INC insiders buying BCRX stock?
In the past 12 months, 0 insiders reported open-market purchases of BCRX worth $0.
Are BIOCRYST PHARMACEUTICALS INC insiders selling BCRX stock?
4 insiders reported sales worth $4.1M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is BCRX's 52-week range?
Over the past year BCRX has traded between $6.24 and $11.11. It last closed at $8.55 on Oct 9, 2026.